Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain

References

• Saadatian-Elahi M, Horstick O, Breiman RF, Gessner BD, Gubler DJ, Louis J, Parashar UD, Tapia R, Picot V, Zinsou J-A, et al. Beyond efficacy: the full public health impact of vaccines. Vaccine. 2016;34(9):1139–47. doi:10.1016/j.vaccine.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Rudan I. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408–16. doi:10.2471/BLT.00.000000.
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJC, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51. doi:10.1111/1469-0691.12461.
   PubMed Web of Science ®Google Scholar
• Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, Riley, ID and Makela, H. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database of Syst Rev. 2009;(4):Cd004977.
   PubMed Web of Science ®Google Scholar
• Ramani RRH, William N, Boulton M, Johnson DR, Zhu B-P. Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study. Am J Pub Health. 2004;94(6):958–59. doi:10.2105/AJPH.94.6.958.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position on pneumococcal vaccines: the polysaccharide vaccine. Wkly Epid Rev 2003;14:110–20.
   Google Scholar
• Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196(9):1346–54. doi:10.1086/524219.
   PubMed Web of Science ®Google Scholar
• Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999;5(3):336–45. doi:10.3201/eid0503.990304.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011;11(10):760–68. doi:10.1016/S1473-3099(11)70090-1.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011;378(9807):1962–73. doi:10.1016/S0140-6736(10)62225-8.
   PubMed Web of Science ®Google Scholar
• Grupo de Trabajo de la Ponencia de Registro y Program de Vacunas. Enfermedad invasora por Streptococcus pneumoniae: implicación de la vacunación con la vacuna conjugada heptavalente. Abril 2006. Madrid (España): Ministerio de Sanidad y Consumo; 2006.
   Google Scholar
• de Xaude C. Dirrección Xeral de Innovación e Xestión da Saúde Pública. Vacunación frente al neumococo (estudio piloto). Santiago de Compostela (España): Conselleria de Xaude; 2010.
   Google Scholar
• Grupo de Trabajo de Neumococo. Nuevas vacunas antineumococicas conjugadas. Madrid (Espana): Ministerio de Sanidad y Politica Social; 2009.
   Google Scholar
• Grupo de Trabajo Vacunación frente a neumococo. Vacunación frente a neumococo en grupos de riesgo, Mayo de 2015. Madrid (España): Ministerio de Sanidad, Servicios Sociales e Igualidad; 2015.
   Google Scholar
• Goldblatt D. Conjugate vaccines. Clin Exp Immunol. 2000;119:1–3. doi:10.1046/j.1365-2249.2000.01109.x.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease — United States, 1998–2003. MMWR Morb Mortal Wkly Rep. 2005;16(54):893–97.
   Google Scholar
• Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O’Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–55. doi:10.1586/erv.12.53.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Grant LR, Weatherholtz RC, Warren JL, O’Brien KL, Hammitt LL. Relating pneumococcal carriage among children to disease rates among adults before and after the introduction of conjugate vaccines. Am J Epidemiol. 2016;183(11):1055–62. doi:10.1093/aje/kwv283.
   PubMed Web of Science ®Google Scholar
• Instituto Galego de Estatistica. Indicadores demograficos anos 2016 e 2017. Santiago de Compostela (España): Xunta de Galicia; 2018. http://www.ige.eu/web/avisolegal.jsp?idioma=gl.
   Google Scholar
• Instituto Nacional de Estadistica. Indicadores demográficos - Definitivos año 2017 Madrid (España): Instituto Nacional de Estadistica; 2018. https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736177003&menu=ultiDatos&idp=1254735573002.
   Google Scholar
• Conselleria de Sanidad. Estrategia SERGAS 2020. Santiago de Compostela (Espana): Xunta de Galicia; 2014.
   Google Scholar
• Gil-Prieto R, Garcia-Garcia L, Alvaro-Meca A, Mendez C, Garcia A, de Miguel AG. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine. 2011;29(3):412–16. doi:10.1016/j.vaccine.2010.11.025.
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad Consumo y Bienestar Social. Conjunto Minimo Basico Datos. Portal Estadistico-Area de Inteligencia de Gestion. Madrid (Espana): Ministerio de Sanidad, Consumo y Bienestar Social (MSCBS); 2010.
   Google Scholar
• Comité Asesor de Vacunas. Actualizacion en vacunacion antineumococica 2010: recomendaciones del Comite Asesor de Vacunas. Madrid (España): Asociación Española de Pediatría; 2010.
   Google Scholar
• Conselleria de Xaude - Dirección Salud Publica. Vacinación antipneumocócica en adultos, Xullo 2017. Santiago de Compostela (España): Xunta de Galicia; 2017.
   Google Scholar
• Conselleria de Xaude. Dirección Xeral de Innovación e Xestión de Saúde Pública. Uso vacina antipneumocócica conxugada grupos risco, Xullo 2014. Santiago de Compostela (España): Xunta de Galicia; 2014.
   Google Scholar
• Boletín Epidemiolóxico de Galicia - Xuño 2012. A Vacinación Infantil Coa Vc-13 En Galicia: O Estudo Piloto. Santiago de Compostela (Spain): Dirección xeral de innovación e xestión da saúde pública – DXIXSP; 2012.
   Google Scholar
• Boletín Epidemiolóxico de Galicia - Xulio 2013. A Vacinación Infantil Coa Vc-13 En Galicia: Duos Años de Estudo Piloto. Santiago de Compostela (Spain): Dirección xeral de innovación e xestión da saúde pública – DXIXSP; 2013.
   Google Scholar
• Boletín Epidemiolóxico de Galicia - Xulio 2015. A Vacinación Infantil Coa Vc-13 En Galicia: Os Catro Anos De Estudo Piloto. Santiago de Compostela (Spain): Dirección xeral de innovación e xestión da saúde pública – DXIXSP; 2015.
   Google Scholar
• Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J. 2010;29(7):607–12. doi:10.1097/INF.0b013e3181d7d09c.
   PubMed Web of Science ®Google Scholar
• Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax. 2010;65(9):770–74. doi:10.1136/thx.2010.137802.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–09. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Givon-Lavi N, Shemer-Avni Y, Bar-Ziv J, Alonso WJ, Greenberg D, Dagan R. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg Infect Dis. 2013;19(7):1084–91. doi:10.3201/eid1907.121625.
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–24. doi:10.1093/cid/ciu006.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Givon-Lavi N, Ben-Shimol S, Ziv JB, Dagan R. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33(36):4623–29. doi:10.1016/j.vaccine.2015.06.062.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Dagan R, Givon-Lavi N, Avital D, Bar-Ziv J, Greenberg D. Use of chest radiography examination as a probe for PCV impact on lower respiratory tract infections in young children. Clin Infect Dis. 2019. doi:10.1093/cid/ciz768.
   PubMedGoogle Scholar
• Ouldali N, Levy C, Minodier P, Morin L, Biscardi S, Aurel M, Dubos F, Dommergues MA, Mezgueldi E, Levieux K, et al. Long-term association of 13-valent pneumococcal conjugate vaccine implementation with rates of community-acquired pneumonia in children. JAMA Pediatr. 2019;173(4):362–70. doi:10.1001/jamapediatrics.2018.5273.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig A, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648599.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP, Low DE. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2(1):e00309–10. doi:10.1128/mBio.00309-10.
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis. 2000;31:1066–78. doi:10.1086/cid.2000.31.issue-4.
   PubMed Web of Science ®Google Scholar
• Stupka JE, Mortensen EM, Anzueto A, Restrepo MI. Community-acquired pneumonia in elderly patients. Aging Health. 2009;5(6):763–74. doi:10.2217/ahe.09.74.
   PubMedGoogle Scholar
• Rivero-Calle I, Pardo-Seco J, Aldaz P, Vargas DA, Mascaros E, Redondo E, Díaz-Maroto JL, Linares-Rufo M, Fierro-Alacio MJ, Gil A, et al. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). BMC Infect Dis. 2016;16(1):645. doi:10.1186/s12879-016-1974-4.
   PubMed Web of Science ®Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013;32(1):133–45. doi:10.1016/j.vaccine.2013.05.005.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, editor. Impact of PCV13 on Invasive Pneumococcal Disease (IPD) Burden and the Serotype Distribution in the U.S. Advisory Committee on Immunization Practices October 2018 Meeting; 2018; Atlanta, GA: US Centers for Disease Control and Prevention.
   Google Scholar
• Ruiz-Contreras J, Picazo J, Casado-Flores J, Baquero-Artigao F, Hernandez-Sampelayo T, Otheo E, Méndez C, Del Amo M, Balseiro C. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Vaccine. 2017;35(35):4646–51. doi:10.1016/j.vaccine.2017.06.070.
   PubMed Web of Science ®Google Scholar
• Moraga-Llop F, Garcia-Garcia JJ, Diaz-Conradi A, Ciruela P, Martinez-Osorio J, Gonzalez-Peris S, Hernández S, de Sevilla MF, Uriona S, Izquierdo C, et al. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage. Pediatr Infect Dis J. 2016;35(4):460–63. doi:10.1097/INF.0000000000001041.
   PubMed Web of Science ®Google Scholar
• Latasa P, Ordobas M, Garrido-Estepa M, Gil de Miguel A, Sanz JC, Barranco MD, Insúa E, García-Comas L. Effectiveness of different vaccine schedules for heptavalent and 13-valent conjugate vaccines against pneumococcal disease in the Community of Madrid. Vaccine. 2017;35(40):5381–87. doi:10.1016/j.vaccine.2017.07.089.
   PubMed Web of Science ®Google Scholar
• Ardanuy C, de la Campa AG, Garcia E, Fenoll A, Calatayud L, Cercenado E, Pérez-Trallero E, Bouza E, Liñares J. Spread of Streptococcus pneumoniae serotype 8-ST63 multidrug-resistant recombinant Clone, Spain. Emerg Infect Dis. 2014;20(11):1848–56. doi:10.3201/eid2011.131215.
   PubMed Web of Science ®Google Scholar
• Calbo E, Diaz A, Canadell E, Fabrega J, Uriz S, Xercavins M, Morera MA, Cuchi E, Rodríguez-Carballeira M, Garau J, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12(9):867–72. doi:10.1111/j.1469-0691.2006.1502_1.x.
   PubMed Web of Science ®Google Scholar
• Camara J, Marimon JM, Cercenado E, Larrosa N, Quesada MD, Fontanals D, Cubero M, Pérez-Trallero E, Fenoll A, Liñares J, et al. Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain. PLoS One. 2017;12(4):e0175224. doi:10.1371/journal.pone.0175224.
   PubMed Web of Science ®Google Scholar
• Ercibengoa M, Arostegi N, Marimón JM, Alonso M, Pérez-Trallero E. Dynamics of pneumococcal nasopharyngeal carriage in healthy children attending a day care center in Northern Spain. Influence of detection techniques on the results. BMC Infect Dis. 2012;12:69. doi:10.1186/1471-2334-12-69.
   PubMed Web of Science ®Google Scholar
• Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174–82. doi:10.1086/524660.
   PubMed Web of Science ®Google Scholar
• Rolo D, Fenoll A, Ardanuy C, Calatayud L, Cubero M, de la Campa AG, Linares J. Trends of invasive serotype 6C pneumococci in Spain: emergence of a new lineage. J Antimicrob Chemother. 2011;66(8):1712–18. doi:10.1093/jac/dkr193.
   PubMed Web of Science ®Google Scholar
• Brandileone MC, Almeida SCG, Minamisava R, Andrade AL. Distribution of invasive Streptococcus pneumoniae serotypes before and 5years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–66. doi:10.1016/j.vaccine.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61(21):394–95.
   PubMedGoogle Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822–25.
   PubMed Web of Science ®Google Scholar
• Wiese AD, Griffin MR, Grijalva CG. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019;18(4):327–41. doi:10.1080/14760584.2019.1582337.
   PubMed Web of Science ®Google Scholar
• Teresa Aguado M, Barratt J, Beard JR, Blomberg BB, Chen WH, Hickling J, Hyde TB, Jit M, Jones R, Poland GA, et al. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017. Vaccine. 2018;36(7):921–31. doi:10.1016/j.vaccine.2017.12.029.
   PubMed Web of Science ®Google Scholar